Blogs

It’s Spring Statement week and we have a webinar on what it means for the sector this Friday; also in this blog - why VPAG needs sorting and a new Series C raise for a BIA member, Brainomix.

In this blog, BIA CEO Steve Bates OBE gives his take on the announcement that the UK government is consulting on introducing a new law to raise the Statutory Scheme payment rate for newer branded medicines from 15.5% to 32.2% of subject companies' NHS sales revenues in the second half of 2025.

Following a number of ‘firsts’ for Stablepharma during 2024, we spoke with Ozgur Tuncer, CEO and Executive Director about a year that has accelerated the commercialisation of the world’s first fridge-free vaccine, SPVX02, for the prevention of Tetanus and Diphtheria.

A big raise as next generation biotech leaders gather, NHS England is abolished, and global trade disputes touch on our industry.

On 6 March 2025, just ahead of International Women’s Day, the BioIndustry Association (BIA) hosted the Women in Biotech Cambridge event—a vibrant gathering of trailblazing women shaping the life sciences landscape.

This week, BIA was invited by the Foreign Secretary to represent UK life sciences in Japan. In Parliament, we're championing a robust industrial strategy. Our new report provides the data and real life experience on womens’ leadership in our sector, while a former Board BIA member joins Duran Duran (sort of).

Last week was a big one for UK life sciences, from the BIA Committee Summit shaping our sector’s future to major leadership changes at UKRI and NHS England. In this week’s update, I explore what these developments mean for our industry, alongside breakthroughs in AI, investment, and accessibility in healthcare.

In this blog, Albert Maguire - King, Media and Communications Executive at the BIA, outlines how the #BIGIMPACT campaign is utilising AI, data science, and tech talent to drive breakthroughs in biotech—ensuring the UK remains at the cutting edge of healthcare and scientific progress.

Rare Disease Day marks an important occasion to raise awareness of rare diseases and the need for action to support people and families living with these conditions.

In this week’s blog, HM Treasury considers ISA changes to enable tax support for growth, a new engineering biology regulatory group gives the UK a strategic edge and a key MHRA webinar on ILAP is upcoming.

David Cooper, UK Project Pursuit at new BIA member Emerson, answers questions about the company.

Dr Danuta Jeziorska outlines that the UK has a unique opportunity to lead in genomics and AI-driven precision medicine, but a critical early-stage funding gap—particularly for drug target discovery companies—threatens its global competitiveness.

The data the biotech industry generates, consumes and shares is very often not only extremely sensitive (expensive to create, the product of some of the finest minds and technically focused facilities on the earth, in some cases connectable to the very fabric of humanity), it’s impossible to de-sensitise once lost to an attacker. 

The relaunched APPG for Life Sciences holds its inaugural parliamentary reception, bringing together MPs, Peers, and sector leaders to showcase UK life sciences innovation.

 This week’s blog explores the dynamic intersection of life sciences, policy, and innovation. From groundbreaking collaborations in the UK to navigating the shifting IP landscape in North America, I reflect on how our sector continues to lead and adapt in a rapidly changing world.

In this article, Giuseppe Amoroso, R&D Tax Advisor for biotech companies, explores the critical role of R&D tax compliance in the biotechnology sector.

Glox Therapeutics' expanded team to support development and commercialisation of precision antibiotics to help overcome antimicrobial resistance.

Apprenticeships offer a cost-effective way to develop talent, bridge skills gaps, and drive business growth—find out how they can deliver real ROI for your organisation.

The UK’s biotech sector continues to break new ground, from sustainable medicine manufacturing to AI-driven healthcare advancements. This week, I analyse key developments shaping the industry, including the launch of the Sustainable Medicine Manufacturing Innovation Programme, the BIA’s role in the government’s Spending Review, and the UK’s leadership in cultivated meat.

Celebrating success for UK life sciences with a landmark week.